BR112014002173A2 - proteínas purificadas - Google Patents
proteínas purificadasInfo
- Publication number
- BR112014002173A2 BR112014002173A2 BR112014002173A BR112014002173A BR112014002173A2 BR 112014002173 A2 BR112014002173 A2 BR 112014002173A2 BR 112014002173 A BR112014002173 A BR 112014002173A BR 112014002173 A BR112014002173 A BR 112014002173A BR 112014002173 A2 BR112014002173 A2 BR 112014002173A2
- Authority
- BR
- Brazil
- Prior art keywords
- compositions
- purified
- purified proteins
- methods
- proteins
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 4
- 102000004127 Cytokines Human genes 0.000 abstract 2
- 108090000695 Cytokines Proteins 0.000 abstract 2
- 238000004113 cell culture Methods 0.000 abstract 2
- 238000002360 preparation method Methods 0.000 abstract 2
- 238000000746 purification Methods 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/545—IL-1
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
- B01D15/18—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
- B01D15/1864—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
- B01D15/361—Ion-exchange
- B01D15/362—Cation-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
- B01D15/361—Ion-exchange
- B01D15/363—Anion-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
- B01D15/3847—Multimodal interactions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Analytical Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161513453P | 2011-07-29 | 2011-07-29 | |
| US201261591727P | 2012-01-27 | 2012-01-27 | |
| PCT/US2012/048631 WO2013019652A1 (en) | 2011-07-29 | 2012-07-27 | Purified proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112014002173A2 true BR112014002173A2 (pt) | 2017-03-01 |
Family
ID=46682907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014002173A BR112014002173A2 (pt) | 2011-07-29 | 2012-07-27 | proteínas purificadas |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20140341843A1 (https=) |
| EP (1) | EP2736524A1 (https=) |
| JP (1) | JP2014522868A (https=) |
| CN (1) | CN104066439A (https=) |
| AU (1) | AU2012290379A1 (https=) |
| BR (1) | BR112014002173A2 (https=) |
| CA (1) | CA2843197A1 (https=) |
| RU (1) | RU2014107743A (https=) |
| SG (1) | SG10201606218WA (https=) |
| WO (1) | WO2013019652A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2952394T3 (es) | 2010-07-29 | 2023-10-31 | Buzzard Pharmaceuticals AB | Antagonistas quiméricos del receptor IL-1 de tipo I |
| EP2968468B1 (en) * | 2013-03-13 | 2021-07-14 | Buzzard Pharmaceuticals AB | Chimeric cytokine formulations for ocular delivery |
| AU2013203043B2 (en) | 2013-03-15 | 2016-10-06 | Takeda Pharmaceutical Company Limited | Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs |
| ES2810813T3 (es) * | 2014-01-24 | 2021-03-09 | Am Pharma Bv | Procesamiento para recuperación y purificación de una fosfatasa alcalina |
| WO2015138844A1 (en) * | 2014-03-13 | 2015-09-17 | Eleven Biotherapeutics, Inc. | Methods for production of stable chimeric cytokine protein formulations in blow fill seal containers |
| RU2729161C2 (ru) * | 2014-10-23 | 2020-08-04 | ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. | Фармацевтические композиции, содержащие варианты пептидов, и способы их применения |
| TW201702380A (zh) * | 2015-02-27 | 2017-01-16 | 再生元醫藥公司 | 宿主細胞蛋白質修飾 |
| CN104710527B (zh) * | 2015-02-28 | 2018-08-24 | 苏州金盟生物技术有限公司 | 一种生物制品的内毒素去除方法 |
| HRP20250718T1 (hr) * | 2016-08-15 | 2025-08-15 | F. Hoffmann-La Roche Ag | Kromatografski postupak za kvantifikaciju neionskog surfaktanta u sastavu koji sadrži neionski surfaktant i polipeptid |
| AU2021262609A1 (en) | 2020-05-01 | 2022-12-22 | Kashiv Biosciences, Llc | An improved process of purification of protein |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA811368B (en) | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
| US5693489A (en) | 1984-03-30 | 1997-12-02 | Associated Universities, Inc. | Cloning and expression of the gene for bacteriophage T7 RNA polymerase |
| US4770781A (en) * | 1986-03-03 | 1988-09-13 | Merck & Co., Inc. | Purification of human interleukin-1 species |
| US4883658A (en) | 1986-04-28 | 1989-11-28 | Holly Frank J | Ophthalmic solution for treatment of dry-eye syndrome |
| US4804539A (en) | 1986-07-28 | 1989-02-14 | Liposome Technology, Inc. | Ophthalmic liposomes |
| US4801686A (en) * | 1986-09-04 | 1989-01-31 | Immunex Corporation | Purification of recombinant interleukin-1 |
| US5278151A (en) | 1987-04-02 | 1994-01-11 | Ocular Research Of Boston, Inc. | Dry eye treatment solution |
| JP2799483B2 (ja) * | 1988-03-09 | 1998-09-17 | 大塚製薬株式会社 | インターロイキン−１β組成物の安定化方法 |
| AU4005289A (en) | 1988-08-25 | 1990-03-01 | Smithkline Beecham Corporation | Recombinant saccharomyces |
| US5075104A (en) | 1989-03-31 | 1991-12-24 | Alcon Laboratories, Inc. | Ophthalmic carboxy vinyl polymer gel for dry eye syndrome |
| EP0502956B1 (en) * | 1989-11-29 | 1997-04-23 | Amgen Boulder Inc. | Production of recombinant human interleukin-1 inhibitor |
| ZA912797B (en) | 1990-05-29 | 1992-12-30 | Boston Ocular Res | Dry eye treatment process and solution |
| ATE257389T1 (de) * | 1992-09-17 | 2004-01-15 | Amgen Inc | Pharmazeutische zusammensetzungen mit interleukin-1 inhibitoren |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| PT938501E (pt) * | 1996-06-07 | 2004-11-30 | Aventis Bulk S P A | Processo para a purificacao de um antagonista do receptor de interleucina-1 humana, a partir de e. coli recombinante |
| ES2312179T3 (es) * | 1996-12-06 | 2009-02-16 | Amgen Inc. | Terapia combinada que utiliza un inhibidor del il-1 para el tratamiento de enfermedades mediadas por el il-1. |
| US7083784B2 (en) | 2000-12-12 | 2006-08-01 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| RS57852B1 (sr) * | 2004-04-02 | 2018-12-31 | Swedish Orphan Biovitrum Ab Publ | Postupci za smanjenje agregacije il-1ra |
| US7700318B2 (en) * | 2004-08-25 | 2010-04-20 | Amprotein Corporation | Chimeric polypeptide and use thereof |
| RU2411957C2 (ru) * | 2004-12-02 | 2011-02-20 | Домантис Лимитед | Способы лечения респираторного заболевания с применением антагонистов рецептора интерлейкина-1 типа 1 |
| SI2173890T1 (sl) | 2007-06-21 | 2011-06-30 | Univ Muenchen Tech | Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost |
| JP2010536341A (ja) | 2007-08-15 | 2010-12-02 | アムニクス， インコーポレイテッド | 生物学的に活性なポリペプチドの特性を改変するための組成物および方法 |
| WO2011063195A2 (en) * | 2009-11-20 | 2011-05-26 | Dr. Reddy's Laboratories Ltd. | Purification of modified cytokines |
| ES2952394T3 (es) * | 2010-07-29 | 2023-10-31 | Buzzard Pharmaceuticals AB | Antagonistas quiméricos del receptor IL-1 de tipo I |
| WO2012103240A2 (en) * | 2011-01-25 | 2012-08-02 | Eleven Biotherapeutics, Inc. | Receptor binding agents |
-
2012
- 2012-07-27 SG SG10201606218WA patent/SG10201606218WA/en unknown
- 2012-07-27 RU RU2014107743/10A patent/RU2014107743A/ru not_active Application Discontinuation
- 2012-07-27 CA CA2843197A patent/CA2843197A1/en not_active Abandoned
- 2012-07-27 CN CN201280046036.2A patent/CN104066439A/zh active Pending
- 2012-07-27 WO PCT/US2012/048631 patent/WO2013019652A1/en not_active Ceased
- 2012-07-27 US US14/235,777 patent/US20140341843A1/en not_active Abandoned
- 2012-07-27 JP JP2014523080A patent/JP2014522868A/ja active Pending
- 2012-07-27 AU AU2012290379A patent/AU2012290379A1/en not_active Abandoned
- 2012-07-27 BR BR112014002173A patent/BR112014002173A2/pt not_active IP Right Cessation
- 2012-07-27 EP EP12748087.9A patent/EP2736524A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| SG10201606218WA (en) | 2016-09-29 |
| CA2843197A1 (en) | 2013-02-07 |
| EP2736524A1 (en) | 2014-06-04 |
| WO2013019652A1 (en) | 2013-02-07 |
| RU2014107743A (ru) | 2015-09-10 |
| US20140341843A1 (en) | 2014-11-20 |
| JP2014522868A (ja) | 2014-09-08 |
| AU2012290379A1 (en) | 2014-02-06 |
| CN104066439A (zh) | 2014-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014002173A2 (pt) | proteínas purificadas | |
| PL3321355T3 (pl) | Sposoby i kompozycje do klinicznego pozyskiwania komórek alogenicznych oraz zastosowania terapeutyczne | |
| EA201400579A1 (ru) | Антитела к il-36r | |
| EA201391719A1 (ru) | Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний | |
| EA201201357A1 (ru) | Антитела к cd40 | |
| BR112014014809A8 (pt) | composições farmacêuticas compreendendo glitazonas e ativadores de nrf2 | |
| EA202190619A1 (ru) | Противовирусные соединения | |
| CR20130560A (es) | Compuestos de bezotiazol y su uso farmacéutico | |
| IN2012DN06629A (https=) | ||
| EA201291157A1 (ru) | Мультивалентные вакцины с синтетическими наноносителями | |
| BR112014009866A2 (pt) | formulações de anticorpos e métodos | |
| UA109010C2 (en) | Morpholino pyrividines and their use in therapy | |
| EA201370018A1 (ru) | Составы рифаксимина и их применение | |
| TN2012000414A1 (en) | Forms of rifaximin and uses thereof | |
| TN2013000378A1 (en) | Anti - sclerostin antibody crystals and formulations thereof | |
| EA201391154A2 (ru) | Способы и композиции для нацеливания на адипоциты у млекопитающих | |
| EA201400771A1 (ru) | Новые производные азетидина, фармацевтические композиции и их применение | |
| PH12015501609A1 (en) | Phenicol antibacterials | |
| BR112014005025A2 (pt) | composição farmacêutica para uso no tratamento de uma doença neurodegenerativa | |
| BR112013030554A2 (pt) | forma cristalina de ciclosporina a, métodos de preparação e métodos para uso da mesma | |
| MX2014004953A (es) | Ligadores basados en tirosina para la conexion desprendible de peptidos. | |
| BR112014000634A2 (pt) | métodos para tratamento de incontinência associada com atividade sexual | |
| EA201400623A1 (ru) | Новые 2h-индазолы в качестве антагонистов рецептора ep | |
| EA201390955A1 (ru) | Слитый белок robo1-fc для применения в лечении гепатокарциномы | |
| EA201491300A1 (ru) | Композиция для назального применения с улучшенной стабильностью |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |